Rocket Pharmaceuticals (RCKT) announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to RP-A601, the company’s investigational adeno-associated virus-based gene therapy for the treatment of PKP2-arrhythmogenic cardiomyopathy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Cautious Hold Rating on Rocket Pharmaceuticals Amid IND Clearance and Clinical Hold Challenges
- Rocket Pharmaceuticals receives FDA clearance of RP-A701
- Rocket Pharmaceuticals Holds Annual Stockholders Meeting
- Rocket Pharmaceuticals price target lowered to $5 from $12 at UBS
- Optimistic Buy Rating for Rocket Pharmaceuticals Despite Gene Therapy Concerns